Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ardelyx reports strong Q4 earnings, poised for product expansion

Ardelyx's Q4 performance reflects revenue growth, improved financial efficiency, and progress towards expanding its product portfolio.
While facing challenges such as regulatory processes and market competition, Ardelyx's strengths lie in successful product launches and a proactive commercial strategy.
Opportunities for Ardelyx include leveraging positive feedback for XPHOZAH, raising additional funds for growth, and diversifying revenue through new product launches.

Ardelyx reports sales growth, readies XPHOZAH launch amid challenges

Ardelyx showed strong sales growth for IBSRELA and is poised for the XPHOZAH launch
Financially, the company raised significant funds and maintains a healthy cash position
Challenges include managing expenses and improving profitability amidst losses
Opportunities lie in upcoming product launches and optimizing financial operations

Ardelyx reports strong Q2 performance amidst legislative challenges and growth opportunities

Ardelyx's Q2 performance reflects growth in IBSRELA sales and overall revenue, despite incurring a net loss.
The company faces challenges from pending legislation and financial burdens related to XPHOZAH launch preparation.
Opportunities lie in the potential of XPHOZAH launch, market reception of IBSRELA, and addressing legislative impacts.

Ardelyx reports strong Q3 earnings, poised for successful XPHOZAH launch

Ardelyx's Q3 performance reflects financial strength and positive market reception for IBSRELA.
Challenges in pricing strategy and market competition require strategic planning for XPHOZAH's launch.
Opportunities lie in leveraging financial stability, physician interest, and promotional activities for XPHOZAH success.
The company's commitment to patient access and learnings from IBSRELA will drive future growth and market penetration.

Ardelyx reports strong revenue growth driven by IBSRELA success

Ardelyx is strategically investing in growth, focusing on sustaining momentum for its products. The company is well-resourced and optimistic about the future performance of IBSRELA and XPHOZAH. Despite challenges in operating expenses, Ardelyx remains committed to its commercialization efforts.

Ardelyx reports robust Q1 performance driven by XPHOZAH success

Ardelyx's Q1 2024 earnings call showcased strong revenue growth, particularly driven by XPHOZAH and IBSRELA. The company's cash position remains healthy, and there is a clear focus on expanding market reach and driving adoption of key therapies.

Ardelyx reports robust Q2 earnings, focuses on patient access advocacy

Ardelyx's Q2 2024 performance reflects strong revenue growth driven by IBSRELA and XPHOZAH, with a focus on shareholder value and patient access advocacy. While facing challenges in legal battles and expense management, the company is poised to capitalize on opportunities through sales force expansion and market differentiation strategies.

Ardelyx (ARDX) reports robust Q3 earnings, navigates Medicare coverage challenges

Ardelyx's Q3 earnings call highlighted strong financial performance, success of key medications, and strategies to address Medicare coverage challenges. The company's focus on patient access, commitment to therapy availability, and positive market impact showcase its growth potential and resilience in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Yamana Gold

Energy Focus

Transocean

Are these penny stocks on your list of small-caps to watch right now? The post Check These Penny Stocks Out As 2021 Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These Penny Stocks Out As 2021 Comes to an End

New Oriental Education & Technology Group

Lloyds Banking Group

Here's three penny stocks you need to add to your watchlist right now The post 3 Hot Penny Stocks For Your Watchlist Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks For Your Watchlist Next Week

Alset EHome International

Progenity

Are any of these penny stocks on your watchlist right now? The post 3 Penny Stocks With Bullish Investor Interest Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks With Bullish Investor Interest Right Now

The shares of Ardelyx Inc (NASDAQ: ARDX) have received a $6 price target from Ladenburg. These are the details.

Ardelyx (ARDX) Stock: $6 Price Target From Ladenburg

Cumberland Pharma

Nautilus Biotechnology

Petros Pharmaceuticals

Are these on your list of penny stocks to buy this week? The post Penny Stocks To Buy This Week: 4 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy This Week: 4 To Watch Right Now

The stock price of Ardelyx Inc (NASDAQ: ARDX) increased by 7.89% in the most recent trading session. This is why it happened.

Ardelyx (ARDX) Stock: Why The Price Increased

ImmunoGen

Skylight Health Group

Why these hot penny stocks exploded today The post These Penny Stocks Exploded Today, Are They On Your List? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Penny Stocks Exploded Today, Are They On Your List?

Shares of Ardelyx Inc. ARDX, +24.56% soared 27.2% on massive volume in midday trading Wednesday, and have now nearly doubled in two days since the company announced plans to launch its treatment for irritable bowel syndrome with constipation (IBS-C) in adults. Trading volume ballooned to 192.8 million shares, which was many multiples of the full-day average of 4.3 million shares, and enough to make the stock the most actively traded on major U.S. exchanges.

Ardelyx stock rockets again on massive volume, after plans to launch IBS-C treatment announced

Ardelyx (ARDX) stock is soaring higher on Wednesday following an update concerning the company's ISB-C treatment in adults. The post ARDX Stock Alert: The IBS Drug News Sending Ardelyx Shares Soaring Today appeared first on InvestorPlace.

ARDX Stock Alert: The IBS Drug News Sending Ardelyx Shares Soaring Today

Citigroup raised the price target on Ardelyx Inc (NASDAQ:ARDX) to $13 from $7, with a Buy rating unchanged. The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022.

Citi, Ladenburg React Positively On Ardelyx's IBS-C Treatment Launch Plans

The stock price of Ardelyx Inc (NASDAQ: ARDX) increased by over 24% during intraday trading today. This is why it happened.

Ardelyx (ARDX): Why The Price Jumped Today

Ardelyx Launching IBSRELA® Second Quarter of 2022

Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.

Implied Volatility Surging for Ardelyx (ARDX) Stock Options

Ardelyx Reports Third Quarter 2021 Financial Results

Ardelyx to Present at the Jefferies London Healthcare Conference

Ardelyx (ARDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Ardelyx (ARDX) This Earnings Season?

Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021

Ardelyx to Pursue Formal Dispute Resolution for Tenapanor

Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021

Ardelyx did not get much clarity from the Type A meeting. Tenapanor's future remains unclear.

Ardelyx: Indecisive Regulators, Frustrated Company, Gruelling Wait For Investors

The stock price of Ardelyx Inc (NASDAQ: ARDX) fell by over 17% today. This is why it happened.

ARDX Stock: Why It Drastically Fell Today

BlackBerry

Globalstar

Puxin Limited - ADR

NeuroBo Pharmaceuticals Inc

Waitr Holdings Inc

There's loads of hot penny stocks worth checking in on today and we're taking a look at what some of the top movers are doing! The post Hot Penny Stocks: Why NEW, ARDX, WTRH, GSAT and NRBO Are Moving Today appeared first on InvestorPlace.

Hot Penny Stocks: Why NEW, ARDX, WTRH, GSAT and NRBO Are Moving Today

Ardelyx Provides Corporate Update Following Type A Meeting with FDA

RADNOR, Pa.--(BUSINESS WIRE)---- $ARDX--Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for Ardelyx Inc. Investors in Securities Fraud Class Action Lawsuit

Kessler Topaz Meltzer & Check, LLP:  Important Deadline Reminder for Ardelyx Inc. Investors in Securities Fraud Class Action Lawsuit

New York, New York--(Newsfile Corp. - September 28, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Ardelyx, Inc. ("Ardelyx") (NASDAQ: ARDX) between August 6, 2020 and July 19, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ardelyx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 28, 2021 - ARDX

News for Ardelyx Stock (ARDX)